 |
PDBsum entry 6qb4
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Antibody fragments structurally enable a drug-Discovery campaign on the cancer target mcl-1.
|
 |
|
Authors
|
 |
J.Luptak,
M.Bista,
D.Fisher,
L.Flavell,
N.Gao,
K.Wickson,
S.L.Kazmirski,
T.Howard,
P.B.Rawlins,
D.Hargreaves.
|
 |
|
Ref.
|
 |
Acta Crystallogr D Struct Biol, 2019,
75,
1003-1014.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Apoptosis is a crucial process by which multicellular organisms control tissue
growth, removal and inflammation. Disruption of the normal apoptotic function is
often observed in cancer, where cell death is avoided by the overexpression of
anti-apoptotic proteins of the Bcl-2 (B-cell lymphoma 2) family, including Mcl-1
(myeloid cell leukaemia 1). This makes Mcl-1 a potential target for drug
therapy, through which normal apoptosis may be restored by inhibiting the
protective function of Mcl-1. Here, the discovery and biophysical properties of
an anti-Mcl-1 antibody fragment are described and the utility of both the scFv
and Fab are demonstrated in generating an Mcl-1 crystal system amenable to
iterative structure-guided drug design.
|
 |
|
|
|
|
 |